1621260-89-6

Basic information

• Product Name: 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzoic acid methyl ester
• Synonyms: 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzoic acid methyl ester
• CAS NO: 1621260-89-6
• Molecular Weight: 371.615
• Mol File: 1621260-89-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzoic acid methyl ester(1621260-89-6)
• EPA Substance Registry System: 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzoic acid methyl ester(1621260-89-6)

Safety Data

• Hazardous Substances Data: 1621260-89-6(Hazardous Substances Data)

Upstream product

• 36692-27-0 2-chlorophenylmagnesium bromide 
• 861514-69-4 methyl 3-bromo-5-formyl-2-hydroxybenzoate 

Downstream Products

• 1621260-90-9 2-bromo-4-(2-chloro-benzyl)-6-hydroxymethylphenol 
• 1208884-75-6 2-bromo-4-(2-chloro-benzyl)-6-hydroxymethylphenol 
• 378763-53-2 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzaldehyde 
• 384825-09-6 furan-2-carboxylic acid (4-{[3-bromo-5-(2-chlorobenzyl)-2-hydroxybenzylidene]amino}phenyl)amide 

Relevant articles and documents

Ligand efficiency based approach for efficient virtual screening of compound libraries

Here we report for the first time the use of fit quality (FQ), a ligand efficiency (LE) based measure for virtual screening (VS) of compound libraries. The LE based VS protocol was used to screen an in-house database of 125,000 compounds to identify aurora kinase A inhibitors. First, 20 known aurora kinase inhibitors were docked to aurora kinase A crystal structure (PDB ID: 2W1C); and the conformations of docked ligand were used to create a pharmacophore (PH) model. The PH model was used to screen the database compounds, and rank (PH rank) them based on the predicted IC50 values. Next, LE-Scale, a weight-dependant LE function, was derived from 294 known aurora kinase inhibitors. Using the fit quality (FQ = LE/LE-Scale) score derived from the LE-Scale function, the database compounds were reranked (PH-FQ rank) and the top 151 (0.12% of database) compounds were assessed for aurora kinase A inhibition biochemically. This VS protocol led to the identification of 7 novel hits, with compound 5 showing aurora kinase A IC50 = 1.29 μM. Furthermore, testing of 5 against a panel of 31 kinase reveals that it is selective toward aurora kinase A & B, with 50% inhibition for other kinases at 10 μM concentrations and is a suitable candidate for further development. Incorporation of FQ score in the VS protocol not only helped identify a novel aurora kinase inhibitor, 5, but also increased the hit rate of the VS protocol by improving the enrichment factor (EF) for FQ based screening (EF = 828), compared to PH based screening (EF = 237) alone. The LE based VS protocol disclosed here could be applied to other targets for hit identification in an efficient manner.